Eli Lilly’s oral selective estrogen receptor degrader (SERD) Inluriyo has won FDA approval in combination for certain patients with metastatic breast cancer as a second-line regimen. The approval expands the SERD portfolio with an all-oral approach aimed at established standards of care. The regimen is specifically for patients whose disease meets the trial-defined criteria for second-line treatment. Lilly’s authorization adds incremental options for clinicians seeking endocrine-therapy strategies that bypass estrogen receptor signaling through targeted degradation. For investors and competitors, the update strengthens Lilly’s position in hormone-driven oncology and keeps pressure on rival SERD programs and sequencing strategies. It also reinforces the company’s broader push in oral, combination endocrine regimens. Regulatory approvals of oncology combinations tend to accelerate adoption quickly when safety profiles and endpoints are clear in registrational studies, though the label specifics determine the speed of uptake.